AMRX · Amneal Pharmaceuticals, Inc.
$17.92
-0.05 (-0.28%)
At close · Jul 24
Market Cap
$5.72B
Shares
319.02M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| Investor Event Transcript | 2026-06-30 | — | |
| 8-K | 2026-05-07 | — | |
| 10-Q | 2026-05-07 | 2026-03-31 | |
| 8-K | 2026-05-07 | 2026-05-06 | |
| 8-K | 2026-04-22 | — | |
| Investor Event Transcript | 2026-03-31 | — | |
| DEF 14A | 2026-03-25 | 2026-05-06 | |
| 10-K | 2026-02-27 | 2025-12-31 | |
| 8-K | 2026-02-27 | — | |
| 8-K | 2026-02-03 | 2026-02-02 | |
| 8-K | 2026-01-28 | 2026-01-23 | |
| 8-K | 2026-01-13 | — | |
| 10-Q | 2025-11-06 | 2025-09-30 | |
| 8-K | 2025-10-30 | — | |
| 10-Q | 2025-08-07 | 2025-06-30 | |
| 8-K | 2025-08-05 | — | |
| 8-K/A | 2025-08-05 | — | |
| 8-K | 2025-08-01 | — | |
| 8-K | 2025-07-24 | — | |
| 8-K | 2025-07-21 | 2025-07-16 | |
| 8-K | 2025-07-21 | — | |
| 8-K | 2025-05-08 | — | |
| 10-Q | 2025-05-07 | 2025-03-31 | |
| 8-K | 2025-05-02 | — | |
| DEF 14A | 2025-03-25 | 2025-05-06 | |
| 8-K | 2025-03-06 | 2025-03-01 | |
| 8-K | 2025-02-28 | — | |
| 10-K | 2025-02-28 | 2024-12-31 | |
| 8-K | 2025-01-15 | — | |
| 8-K/A | 2024-11-12 | 2024-11-08 | |
| 10-Q | 2024-11-12 | 2024-09-30 | |
| 8-K | 2024-11-08 | 2024-09-30 | |
| 8-K | 2024-10-01 | — | |
| 10-Q | 2024-08-09 | 2024-06-30 | |
| 8-K | 2024-08-09 | 2024-08-07 | |
| 10-Q | 2024-05-08 | 2024-03-31 | |
| 8-K | 2024-05-07 | 2024-05-02 | |
| 8-K | 2024-05-03 | — | |
| DEF 14A | 2024-03-22 | 2024-05-02 | |
| 10-K | 2024-03-14 | 2023-12-31 | |
| 8-K | 2024-03-01 | — | |
| 8-K | 2024-01-10 | — | |
| 8-K | 2023-12-15 | — | |
| 8-K/A | 2023-12-15 | 2023-11-07 | |
| 8-K | 2023-11-14 | — | |
| 10-Q | 2023-11-09 | 2023-09-30 | |
| 8-K | 2023-11-07 | — | |
| 8-K | 2023-10-23 | — | |
| 8-K | 2023-10-17 | 2023-10-16 | |
| 10-Q | 2023-08-08 | 2023-06-30 |
Showing 1–50 of 109 filings
Key facts
CIK
1723128
CUSIP
03168L105
13F (30d)
53 filings
53 filers
Visit website
Investor relations